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Background: In Guyana, chloroquine + primaquine is used for the treatment of vivax malaria. A worldwide increase
of chloroquine resistance in Plasmodium vivax led to questioning of the current malaria treatment guidelines.
A therapeutic efficacy study was conducted using artemether-lumefantrine + primaquine against P. vivax to
evaluate a treatment alternative for chloroquine.
Methods: From 2009 to 2010, a non-controlled study in two hospitals in Guyana was conducted. A total 61
patients with P. vivax infection were treated with artemether-lumefantrine as a six-dose regimen twice a day for
three days with additional 0.25 mg/kg/d primaquine at day 0 for 14 days. Clinical and parasitological parameters
were followed on days 0,1,2,3,7,14 and 28 in agreement with WHO guidelines. Plasmodium vivax DNA from eight
patients was analysed for pvmdr1, molecular marker of resistance.
Results: Artemether-lumefantrine cleared 100% of parasites on day 1, but two patients (3%) had recurrence of
parasites on day 28, suggesting relapse. No pvmdr1 Y976F polymorphism was detected. The treatment regimen was
well tolerated.
Conclusions: In Guyana, artemether-lumefantrine represents an adequate treatment option against P. vivax when
combined with primaquine. Availability of this alternative will be of great importance in case of emerging
chloroquine resistance against P. vivax.
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Approximately 216 million malaria cases were reported
world-wide in 2010 [1]. Outside of Africa, the most
widely distributed species is Plasmodium vivax, followed
by Plasmodium falciparum [1]. In South America, 1–1.2
million cases of malaria are reported annually with
P. vivax responsible for three quarters and P. falciparum
for one quarter of cases [2].
Artemisinin-based combination therapy (ACT) has
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reproduction in any medium, provided the orof malaria and is responsible for the reduction of malaria
infections worldwide [3-7]. In recent years, reports from
the border between Thailand and Cambodia [8,9] show
resistance from P. falciparum to artemisinin-derivatives.
Although in vitro resistance to artemether is reported
for P. falciparum from South America [10], so far there
is no evidence for treatment failures. Until now, only in-
sufficient information on treatment outcomes with ACT
for the treatment against P. vivax is available.
In Guyana, 42.3% of all malaria cases between 2005
and 2009 were caused by P. falciparum and 51.3% by P.
vivax. The number of malaria cases declined rapidly until
2007, but increased slightly in 2009, with 93% of the
population still being at risk of contracting malaria [1].
Anti-malarial drug policies in South American coun-
tries, including Guyana, use ACT for uncomplicatedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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vivax infections.
Chloroquine resistance against P. vivax was first
reported in 1989 from Papua New Guinea [11]. Since
then various countries, including Myanmar, Turkey, Ethi-
opia, Vietnam, Indonesia, Korea and Madagascar reported
treatment failures with chloroquine [1,12-16]. Thailand
reported its first chloroquine resistant P. vivax cases in
2011 [17], while in India chloroquine treatment seems
still to be effective [18]. Reports from Colombia, Brazil,
and Guyana [19] indicate chloroquine resistance appear-
ing in numerous regions of South America [20,21].
This study aims to assess artemether-lumefantrine +
primaquine as an alternative treatment option for P. vivax
malaria, as a decline in susceptibility towards chloroquine
can be predicted for the coming years. In the light of poor
access to diagnostic facilities and emerging chloroquine
resistance it is important to test the efficacy of
artemether-lumefantrine as a common malaria treatment
in Guyana. In remote areas, WHO recommends the use
of rapid tests for malaria diagnosis. While several of these
commercially available tests showed very good perfor-
mances, their sensitivity and specificity for vivax Malaria
is generally lower than for falciparum malaria. Since mal-
aria species diagnosis could be uncertain, the issue of
treatment efficacy of a single common treatment for all
circulating plasmodium species had to be addressed.
Further the study aims to screen for pvmdr1 single-
nucleotide polymorphism at codon Y976F, suspected to
be involved in P. vivax resistance to chloroquine [22].
Methods
Patient enrolment, treatment and follow-up procedures
A prospective multicentre study was conducted in 2009/
2010 for artemether-lumefantrine + primaquine against
P. vivax. Samples have been collected at two sites, the
Malaria clinic Georgetown, situated in the administrative
district 4 (Demerara-Mahaica; pop. 310.320), and at Port
Kaituma Hospital in region 1 (Barima-Waini; pop.
24.275) of Guyana.
Included were all patients older than six month,
weighing more than 10 kg and with a parasitological
confirmed P. vivax mono-infection.
Patients were excluded from the study, if any of the fol-
lowing occurred: (i) presence of general danger signs in
children aged under five years or signs of severe falcip-
arum malaria according to the definitions of WHO [23],
(ii) presence of severe malnutrition (defined as a child <5
years of age with a weight-for-height z-score < −3, with
symmetrical oedema involving at least the feet or with a
mid-upper arm circumference <110mm), (iii) history of
hypersensitivity reactions or contraindications to any of
the medications being tested, (iv) a positive pregnancy
test or breastfeeding, (v) unable to or unwilling to takecontraceptives, (vi) women between 12–26 years old in
order to avoid potentially pregnant participants, (vii) use
of anti-malarial drugs outside of the study protocol or
regular medication, which may interfere with anti-
malarial pharmacokinetics, (viii) detection of mixed mal-
arial infections during follow-up, (ix) presence of febrile
conditions due to diseases other than malaria, (x) with-
drawal of consent, (xi) loss to follow-up, (xii) protocol
violation, or (xiii) death due to a non-malaria illness.
All study participants were treated with the treatment
regimen used for P. falciparum infections, according to
the national drug policy. They received artemether-
lumefantrine (Novartis, batch number F1375, expiry
date: 01.01.2011) as a six-dose regimen twice a day for
three days and additional 0.25 mg/kg/d primaquine
(NEW GPC INC Guyana, batch number B10392, expiry
date 01.09.2011) for 14 days. The treatment dose was re-
administered, if patients vomited during 30 minutes after
administration. Patients repeatedly vomiting after their
first dose of study medication were excluded from the
study. The three-day artemether-lumefantrine treatment
was directly supervised on site, while the intake of
primaquine was not directly observed. The study partici-
pants were not checked for glucose-6-phosphate de-
hydrogenase (G6PD) deficiency prior to primaquine
administration, as its prevalence in Guyana is assumed
to be low; however accurate information on this defi-
ciency in Guyana is scarce. When participants presented
symptoms of haemolytic anaemia (jaundice, dark urine,
abdominal pain, back pain, lowered haemoglobin level)
during the follow-up visits, the primaquine treatment
had to be stopped and they were excluded from the
study.
Outcome measures
Treatment outcomes were classified on the basis of the
parasitological and clinical outcome according to the latest
WHO guidelines [24], which classifies all patients as having
early treatment failure, late clinical failure, late parasito-
logical failure or an adequate clinical and parasitological
response (ACPR). The ACPR was calculated for day 14
and day 28.
Laboratory procedures
Clinical examination, including measurement of the axil-
lary temperature and Giemsa staining of thick and thin
blood films, was carried out on days 0, 1, 2, 3, 7, 14, 21,
and 28. Thick and thin blood smears were prepared
from finger sticks. After Giemsa staining, each slide was
examined microscopically independently by two experi-
enced technicians at the collection site and again at the
Malaria Research Unit, University Lyon 1. The parasit-
aemia was recorded as number of asexual parasites
counted per 200 white blood cells present in the thick
Table 1 Demographic, parasitological and clinical
features of patients enrolled in the study
n=74
Age (median, range) 24 (5–57)
Male/female 67/7
baseline parasitaemia (mean, range, /μl) 3920 (30–29100)





Baseline Temperature at admission (mean, range, °C) 36.6 (36.0-39.2)
Developed PV parasitaemia during follow-up 2 (2.7%)
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no parasite had been found in 100 high-power fields. On
days 0, 7, 14, 21 and 28 blood was blotted onto filter
paper during follow-up and stored for DNA analysis.
DNA extraction and amplification
DNA was extracted from blood spots on filter paper
with resin-based Instagene Matrix (Bio-Rad, Marnes la
Coquette, France), as described before [25]. Genus-
specific primers targeting the 18s rRNA were used to
screen samples for the presence of Plasmodium. The
identification of the parasite species was confirmed with
species-specific primers (25), using LightCycler (Roche)
real-time PCR. DNA was only available for a subset of
eight P. vivax cases.
Plasmodium vivax mdr1 gene
Detection of SNPs in pvmdr1 (Y976F) was performed on
the eight P. vivax cases using a LightCycler system (Roche)
and fluorescence resonance energy transfer technology.
Primers and probes were designed and synthesized by TIB
Molbiol (DNA Synthesis Service, Berlin, Germany). The
polymerase chain reaction mixture and assay conditions
were used as described in detail elsewhere [22,26,27].
Ethical approval
The study protocol was reviewed and approved by the
Ethics Committee of the Ministry of Health of Guyana.
Informed written consent was provided by all patients or
their parents/guardians before inclusion in the study.
Results
Study population
A total of 561 patients were screened for possible enrol-
ment into the study and 74 (13.2%) patients met the in-
clusion criteria. The Georgetown hospital contributed
87.8% (n=65) of patients, 12.2% (n=9) were recruited at
the Port Kaituma Hospital. Among the patients included,
90.5% were male, 9.5% female, with the majority of all
participants (86.5%) being between 15–49 years old.
The different ethnicities of Guyana were representa-
tively distributed with 47.3% from mixed ethnicities,
24.3% East Indians, 16.2% Amerindians, 10.8% Afro-
guyanes and 1.4% of other groups. In total, 98% of the
study population originated from the three highest mal-
aria endemic regions 1, 7 and 8. The patients presented
with the following symptoms in the preceding 24h: (i)
Fever 20.3%, (ii) vomiting 1.4%, (iii) diarrhoea 2.8%, (iv)
problems with coordination 1.4%, (v) dizziness or faint-
ing 4.1%. However the fever incidence will be underesti-
mated due to frequent self-medication with antipyretic
drugs. The mean parasitaemia counts were 3,920 para-
sites/μl ranging from a maximum of 29,100 parasites/μl
to a minimum of 30 parasites/μl (Table 1).Out of the 74 included patients, nine patients were
lost for follow-up and four violated the protocol, result-
ing in 61 patients, which completed the study (Figure 1).Treatment study
For all patients receiving treatment fever abated and para-
sites were cleared at day 1. Two patients were found with
parasitaemia at day 28 of the follow-up period, showing a
parasite density of 487/μl and 780/μl respectively. The
crude ACPR was 61/61 (100%) by day 14, decreasing to
59/61 (97%) by day 28. All patients tolerated the treatment
well with very few side effects and no serious adverse
events observed. No participants had to be excluded for
haemolytic anaemia after primaquine administration.
In a subset of eight patients, the P. vivax mono-infection
was PCR-confirmed. The others were microscopically con-
firmed by three independent readers. DNA from the para-
sites from the eight confirmed cases underwent screening
for pvmdr1 single-nucleotide polymorphism at codon
Y976F. No mutations were found.Discussion
The study assessed artemether-lumefantrine + prima-
quine as a treatment option against P. vivax. Chloro-
quine and primaquine have been used worldwide against
P. vivax as first-line drugs since 1946 and 1950 respect-
ively. Reports from South-American countries such as
Colombia and Brazil [20,21] on decreasing chloroquine
efficacy against P. vivax and a change of drug policies
from chloroquine to ACT for vivax infections in four
countries (Solomon Islands, Vanuatu, PNG and Papua
(Indonesia)) [1], led to the question for an alternative
treatment option in Guyana. So far only a few studies
have examined artemether-lumefantrine as a treatment
option for P. vivax and even less studies looked at
artemether-lumefantrine and primaquine.
All patients in the study cleared parasites on day 1,
which makes artemether-lumefantrine an efficacious
Figure 1 Flow chart of the study procedure.
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malaria. No severe side effects or adverse events were
observed, similar to other studies, which show a good
safety profile for artemether-lumefantrine alone [28-31]
and for artemether-lumefantrine in combination with
primaquine [30], when used for P. vivax infections. Drug
interactions between the two drugs seem to be unlikely
[32].
Two patients (2.7%) presented with parasitological fail-
ure at day 28. In one of those patients P. vivax was
PCR-confirmed at day 28, with negative PCRs on day 7,
14 and 21. It can be assumed that the new parasitaemia
derived from relapse, rather than recrudescence, al-
though a new infection or a recrudescence cannot be
ruled out completely since there is no evidence that
genotyping of P. vivax parasites may help to distinguish
these events [33]. Frequent relapses with artemether-
lumefantrine have been described, due to the short half-
life of lumefantrine [28]. However, a combination with a
longer-acting partner drug, such as piperaquine would
only delay the P. vivax relapse, but not prevent it. Lume-
fantrine on the other hand is less likely to induce resist-
ance compared to long half-life drugs as chloroquine or
piperaquine [34]. In a situation, where primaquine can
be administered in a safe and compliant manner, prima-
quine is the ideal drug for preventing relapse. However,
a concerning rate of 24.5% resistance to primaquine has
been described in Brazil [35], which could be one reason
for the two treatment failures, observed in the study.
Another reason might be a poor compliance to the un-
supervised primaquine treatment.
With recent reports clearly demonstrating severe P. vivax
infections resembling the course of malign P. falciparuminfections [36,37] the application of a sufficient therapy
has to be ensured. Therefore the continuing surveillance
of chloroquine efficacy is of great importance. Studying
the history of anti-malarial drug resistance development
worldwide, it is not hard to predict that we also will
encounter frequent treatment failures due to chloroquine
in the upcoming years in South America.
A drawback to this study is that only eight patients
could be screened for pvmdr1 single-nucleotide poly-
morphism and no mutations in codon Y976F were
found. Low parasitaemia and sub-optimal sample storage
conditions might partly explain the poor usefulness of
the PCR method with these samples, while it usually
works well with many other blood spot samples. No
conclusions can be drawn on any resistance associated
with pvmdr1 polymorphism. One out of the two patients
with treatment failure was tested for Y976F mutation,
but was wild type. In total, 90% of the study participants
were male. In Guyana, malaria affects many more males
than females at a ratio of almost 4:1 (males 78.2% and
females 21.8%). This reflects the fact, that the migrant
populations, primarily miners, are by far the most
affected group. In addition to that all women aged 12 to
26 were excluded, in order to avoid potential pregnant
study participants. 60% of all reported malaria cases
occur in the Amerindian population, to which 16.2% of
the study participants belong [38].
A switch of drug policies in Guyana to artemether-
lumefantrine + primaquine for P. vivax infections would
establish a common treatment for both circulating
Plasmodium species, which are P. falciparum and P.
vivax. Artemether-lumefantrine is highly effective against
P. falciparum in Guyana, based on a study conducted in
2007/2008 (National Malaria Control Program, unpub-
lished data). A common treatment could result in a num-
ber of advantages. Reports from Thailand and Indonesia
detected up to 23% of P. falciparum infections being
wrongly diagnosed as P. vivax, leading to inappropriate
treatment with chloroquine [39,40]. ACT has also shown
to clear P. vivax more quickly than chloroquine [41].
Treating P. falciparum with artemether-lumefantrine +
primaquine would have the advantage of also treating
potential dormant P. vivax hypnozoites, which are
thought to become activated due to P. falciparum
infections, thereby explaining the high number of vivax
infections after P. falciparum treatment [33].
Keeping chloroquine in the market, could lead to its
administration against P. falciparum in the private sec-
tor. Disadvantages of a common treatment will be the
higher price for ACT as well as a decreased impetus for
laboratories and hospitals in performing a correct plas-
modium species diagnostic. The prescription of prima-
quine to all malaria cases without prior testing for G6PD
deficiency presents a potential risk for severe haemolytic
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deficiency is an infrequent trait in Guyana.
Conclusions
This study shows excellent efficacy for artemether-
lumefantrine in combination with primaquine against
P. vivax infections. The treatment efficacy for chloro-
quine for P. vivax must be under close surveillance in
Guyana. Should resistance against P. vivax increase,
the tested regimen with artemether-lumefantrine +
primaquine will be a more than equal alternative and
drug policies should be switched.
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